Recurrent vaginal shedding of herpes simplex type 2 virus in the mouse and effects of antiviral therapy

Antiviral Research

Volumn 86, Issue 2, 2010, Pages 188-195

  Farley, Nicholas ^a   Bernstein, David I ^a   Bravo, Fernando J ^a   Earwood, Julie ^a   Sawtell, Nancy ^a   Cardin, Rhonda D ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Animal model; Genital herpes; Herpes simplex virus; Recurrent HSV shedding

Indexed keywords

ACICLOVIR; CYCLOPHOSPHAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; IMMUNOCOMPETENCE; LATENT VIRUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECURRENT INFECTION; SURVIVAL RATE; VAGINA SMEAR; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS SHEDDING;

ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; DNA, VIRAL; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; MALE; MICE; POLYMERASE CHAIN REACTION; RECURRENCE; SURVIVAL ANALYSIS; VAGINA; VIRUS SHEDDING;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 2; MUS; SIMPLEXVIRUS;

EID: 77951298563     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.02.317     Document Type: Article

References (31)

1. Bernstein D.I., Farley N., Bravo F.J., Earwood J., McNeal M., Fairman J., Cardin R. The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs. Vaccine 2009.
2. Bourne N., Stanberry L.R., Kern E.R., Holan G., Matthews B., Bernstein D.I. Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection. Antimicrob. Agents Chemother. 2000, 44:2471-2474.
3. Centifanto-Fitzgerald Y., Caldwell D.R., Yates F. Herpes simplex virus: recurrent and nonrecurrent strains. Proc. Soc. Exp. Biol. Med. 1987, 185:484-492.
4. Efstathiou S., Field H.J., Griffiths P.D., Kern E.R., Sacks S.L., Sawtell N.M., Stanberry L.R. Herpes simplex virus latency and nucleoside analogues. Antiviral Res. 1999, 41:85-100.
5. Field H.J., Tewari D., Sutton D., Thackray A.M. Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model. Antimicrob. Agents Chemother. 1995, 39:1114-1119.
6. Gill T.A., Morley P.J., Sweet C. Replication-defective mutants of mouse cytomegalovirus protect against wild-type virus challenge. J. Med. Virol. 2000, 62:127-139.
7. Haynes J.R., Arrington J., Dong L., Braun R.P., Payne L.G. Potent protective cellular immune responses generated by a DNA vaccine encoding HSV-2 ICP27 and the E. coli heat labile enterotoxin. Vaccine 2006, 24:5016-5026.
8. Jerome K.R., Huang M.L., Wald A., Selke S., Corey L. Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. J. Clin. Microbiol. 2002, 40:2609-2611.
9. Johnson A.J., Nelson M.H., Bird M.D., Chu C.F., Milligan G.N. Herpes simplex virus (HSV)-specific T cells activated in the absence of IFN-gamma express alternative effector functions but are not protective against genital HSV-2 infection. J. Reprod. Immunol. 2010, 84:8-15.
10. Kang S., Seo S., Hill J., Kwon B., Lee H., Cho H., Vinay D. Changes in gene expression in latent HSV-1-infected rabbit trigeminal ganglia following epinephrine iontophoresis. Curr. Eye Res. 2003, 26:225-229.
11. Kern E.R. Acyclovir treatment of experimental genital herpes simplex virus infections. Am. J. Med. 1982, 73:100-108.
12. Kern E.R., Richards J.T., Overall J.C., Glasgow L.A. Acyclovir treatment of experimental genital herpes simplex virus infections. I. Topical therapy of type 2 and type 1 infections of mice. Antiviral Res. 1983, 3:253-267.
13. Magaret A., Johnston C., Wald A. Use of the designation " shedder" in mucosal detection of herpes simplex virus DNA involving repeated sampling. Sex. Transm. Infect. 2009.
14. Mayaud P., Nagot N., Konate I., Ouedraogo A., Weiss H.A., Foulongne V., Defer M.C., Sawadogo A., Segondy M., Van de Perre P. Effect of HIV-1 and antiretroviral therapy on herpes simplex virus type 2: a prospective study in African women. Sex. Transm. Infect. 2008, 84:332-337.
15. Mertz G.J., Benedetti J., Ashley R., Selke S.A., Corey L. Risk factors for the sexual transmission of genital herpes. Ann. Intern. Med. 1992, 116:197-202.
16. Milligan G.N., Bernstein D.I. Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology 1997, 229:259-268.
17. Muller W.J., Dong L., Vilalta A., Byrd B., Wilhelm K.M., McClurkan C.L., Margalith M., Liu C., Kaslow D., Sidney J., Sette A., Koelle D.M. Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection. J. Gen. Virol. 2009, 90:1153-1163.
18. Overall J.C., Kern E.R., Schlitzer R.L., Friedman S.B., Glasgow L.A. Genital herpes virus hominis infection in mice. I. Development of an experimental model. Infect. Immun. 1975, 11:476-480.
19. Parr E.L., Holliday E.M., Collard M.W., Parr M.B. Observations on recovery from and recurrence of HSV-2 infections in adult mice that were rescued from lethal vaginal infection by antiviral therapy. Arch. Virol. 2005, 150:1885-1902.
20. Parr M.B., Kepple L., McDermott M.R., Drew M.D., Bozzola J.J., Parr E.L. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab. Invest. 1994, 70:369-380.
21. Sacks S.L., Griffiths P.D., Corey L., Cohen C., Cunningham A., Dusheiko G.M., Self S., Spruance S., Stanberry L.R., Wald A., Whitley R.J. HSV shedding. Antiviral Res. 2004, 63(Suppl. 1):S19-S26.
22. Sawtell N.M., Thompson R.L., Stanberry L.R., Bernstein D.I. Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo. J. Infect. Dis. 2001, 184:964-971.
23. Schiffer J.T., Corey L. New concepts in understanding genital herpes. Curr. Infect. Dis. Rep. 2009, 11:457-464.
24. Stanberry L.R. Evaluation of herpes simplex virus vaccines in animals: the guinea pig vaginal model. Rev. Infect. Dis. 1991, 13(Suppl. 11):S920-S923.
25. Thackray A.M., Field H.J. Comparison of effects of famciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model. Antimicrob. Agents Chemother. 1996, 40:846-851.
26. Thackray A.M., Field H.J. The influence of cyclosporing immunosuppression on the efficacy of famciclovir or valaciclovir chemotherapy studied in a murine herpes simplex virus type 1 infection model. Antivir. Chem. Chemother. 1997, 8:317-326.
27. Thackray A.M., Field H.J. Persistence of infectious herpes simplex virus type 2 in the nervous system in mice after antiviral chemotherapy. Antimicrob. Agents Chemother. 2000, 44:97-102.
28. Wald A. Herpes simplex virus type 2 transmission: risk factors and virus shedding. Herpes 2004, 11(Suppl. 3):130A-137A.
29. Wald A., Corey L., Cone R., Hobson A., Davis G., Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J. Clin. Invest. 1997, 99:1092-1097.
30. Wald A., Zeh J., Selke S., Warren T., Ryncarz A.J., Ashley R., Krieger J.N., Corey L. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N. Engl. J. Med. 2000, 342:844-850.
31. Zhu J., Koelle D.M., Cao J., Vazquez J., Huang M.L., Hladik F., Wald A., Corey L. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J. Exp. Med. 2007, 204:595-603.